Real-World Outcomes and Biomarker Analysis Based on Routine Clinical, Laboratory, and Pathologic Parameters in Metastatic or Unresectable Esophageal Cancer Treated with First-Line Anti-PD-1 Plus Fluoropyrimidine and Platinum.

CPS 10–49 showed a trend toward shorter survival compared to CPS ≥50 (HR, 2.28; 95% CI, 0.74–7.00; p = 0.152), although this difference was not statistically significant, possibly due to the limited sample size. 3.6.

also in 53,322 other papers

Although CPS 10–49 did not reach statistical significance for OS, it tended toward inferior survival compared to CPS ≥ 50, suggesting a graded association between CPS level and treatment outcomes.

also in 111,027 other papers